Enhertu Gets Accelerated Approval for HER2-Mutant Metastatic NSCLC
The accelerated approval was based on data from the phase 2 DESTINY-Lung02 trial that included adults with HER2-mutant metastatic NSCLC after 1 prior systemic therapy.
The accelerated approval was based on data from the phase 2 DESTINY-Lung02 trial that included adults with HER2-mutant metastatic NSCLC after 1 prior systemic therapy.
Adding nivolumab to neoadjuvant platinum-based chemotherapy can improve survival in patients with stage IIIA-B non-small cell lung cancer, new data suggest.
Sugemalimab consolidation improved progression-free survival, when compared with placebo, in patients with unresectable, stage III non-small cell lung cancer.
Sintilimab, IBI305, and chemotherapy could be a new standard of care for patients with EGFR-mutant NSCLC that progressed on an EGFR TKI.
Guideline-adherent care was associated with better survival, regardless of disease stage.
Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.
Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.
The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.